Your browser doesn't support javascript. This means that the content or functionality of our website will be limited or unavailable. If you need more information about Vinnova, please contact us.
You're using version {0} of the web browser {1}. This means that the content or functionality of our website may be limited or unavailable. We recommend that you upgrade your browser to optimise your experience of our website.
New therapeutic against schizophrenia
| Reference number | 2020-04891 |
| Coordinator | Beactica Therapeutics AB |
| Funding from Vinnova | SEK 0 |
| Project duration | March 2021 - February 2022 |
| Status | Completed |
| Venture | Innovation projects in enterprises |
| Call | Innovation projects in SMEs 2020 |
Last updated 9 November 2021
Reference number 2020-04891
